Advertisement

Increasing Imaging Value to Breast Cancer Care Through Prognostic Modeling of Multiparametric MRI Features in Patients Undergoing Neoadjuvant Chemotherapy

Published:January 13, 2022DOI:https://doi.org/10.1016/j.acra.2021.12.019
      As we move toward personalized medicine and in the setting of what is increasingly understood as a heterogeneous disease, breast imaging is poised to play a key role in breast cancer. In addition to its well-established diagnostic utility, breast imaging has the potential to predict response to treatment and aid in therapy modulation.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Academic Radiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Goldhirsch A
        • Glick JH
        • Gelber RD
        • et al.
        Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer.
        J Clin Oncol. 2001; 19: 3817-3827
        • von Minckwitz G
        • Rezai M
        • Loibl S
        • et al.
        Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
        J Clin Oncol. 2010; 28: 2015-2023
        • Thomas E
        • Holmes FA
        • Smith TL
        • et al.
        The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial.
        J Clin Oncol. 2004; 22: 2294-2302
        • Yankeelov TE
        • Atuegwu N
        • Hormuth D
        • et al.
        Clinically relevant modeling of tumor growth and treatment response.
        Sci Transl Med. 2013; 5: 187ps9
        • von Minckwitz G
        • Kummel S
        • Vogel P
        • et al.
        Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study.
        J Natl Cancer Inst. 2008; 100: 552-562
        • Botsikas D
        • Bagetakos I
        • Picarra M
        • et al.
        What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?.
        Eur Radiol. 2019; 29: 1787-1798
        • Andre F
        • Mazouni C
        • Liedtke C
        • et al.
        HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
        Breast Cancer Res Treat. 2008; 108: 183-190
        • Li Y
        • Zhou Y
        • Mao F
        • et al.
        The diagnostic performance of minimally invasive biopsy in predicting breast pathological complete response after neoadjuvant systemic therapy in breast cancer: a meta-analysis.
        Front Oncol. 2020; 10: 933
        • Choi JH
        • Lim HI
        • Lee SK
        • et al.
        The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.
        J Surg Oncol. 2010; 102: 392-397
        • Jun W
        • Cong W
        • Xianxin X
        • et al.
        Meta-analysis of quantitative dynamic contrast-enhanced MRI for the assessment of neoadjuvant chemotherapy in breast cancer.
        Am Surg. 2019; 85: 645-653
        • Rauch GM
        • Adrada BE
        • Kuerer HM
        • et al.
        Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer.
        AJR Am J Roentgenol. 2017; 208: 290-299
        • Abdel Razek AA
        • Gaballa G
        • Denewer A
        • et al.
        Diffusion weighted MR imaging of the breast.
        Acad Radiol. 2010; 17: 382-386
        • Chu W
        • Jin W
        • Liu D
        • et al.
        Diffusion-weighted imaging in identifying breast cancer pathological response to neoadjuvant chemotherapy: a meta-analysis.
        Oncotarget. 2018; 9: 7088-7100
        • Partridge SC
        • Zhang Z
        • Newitt DC
        • et al.
        Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 multicenter trial.
        Radiology. 2018; 289: 618-627
        • Wu LM
        • Hu J
        • Gu HY
        • et al.
        Can diffusion-weighted magnetic resonance imaging (DW-MRI) alone be used as a reliable sequence for the preoperative detection and characterisation of hepatic metastases? A meta-analysis.
        Eur J Cancer. 2013; 49: 572-584
        • McDonald ES
        • Romanoff J
        • Rahbar H
        • et al.
        Mean apparent diffusion coefficient is a sufficient conventional diffusion-weighted MRI metric to improve breast MRI diagnostic performance: results from the ECOG-ACRIN cancer research group A6702 diffusion imaging trial.
        Radiology. 2021; 298: 60-70
        • Zhao R
        • Lu H
        • Li Y
        • et al.
        Nomogram for early prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using dynamic contrast-enhanced and diffusion- weighted MRI.
        Acad Radiol. 2022;
        • Baltzer P
        • Mann RM
        • Iima M
        • et al.
        Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group.
        Eur Radiol. 2020; 30: 1436-1450
      1. RSNAQuantitativeImagingBiomarkersAlliance. QIBAProfile:Diffusion- Weighted Magnetic Resonance Imaging (DWI). Available at: https://qibawiki.rsna.org/index.php/Profiles. Accessed November 20, 2021.

        • Whisenant JG
        • Romanoff J
        • Rahbar H
        • et al.
        Factors affecting image quality and lesion evaluability in breast diffusion-weighted MRI: observations from the ECOG-ACRIN cancer research group multisite trial (A6702).
        J Breast Imaging. 2021; 3: 44-56
        • McKay JA
        • Church AL
        • Rubin N
        • et al.
        A comparison of methods for high-spatial-resolution diffusion-weighted imaging in breast MRI.
        Radiology. 2020; 297: 304-312